BPC-157 is an unlicensed synthetic peptide not approved by the MHRA, EMA, or FDA for human use
It is administered regularly based on the patient's medical condition, either weekly or daily
This step becomes critical for long protocols or when obtained results deviate from published expectations
doi: 10.1016/j.micpath.2005.05.002 137 GiuffridaM
The search terms included irritable bowel syndrome, microbiota, microbiome, and IBS treatment. These search items were combined with the AND operator to additional search terms for the relevant sections of the review, including pathophysiology, animal studies, metagenomics, prebiotics, probiotics, fecal transplantation, symbiotic, postbiotic, metagenome, fungal treatment, archaebiotics, phage therapy, 3-D gut modeling, dietary intervention, pathogenesis, FODMAP, diet, meta-analysis, and future therapy. All authors contributed toward the literature search
Brain autoimmunity and intestinal microbiota: 100 trillion game changers
